As of Jun 22, 2026, WST's PEG ratio of 2.56 reflects its valuation relative to its growth. This value reflects a P/E ratio of 43.84 measured against EPS growth of 17.1%.
West Pharmaceutical Services's ten years historical PEG ratio averages out to 5.62. Compared to historical data, WST's 2.56 PEG ratio represents a decrease of 54%. WST reached its maximum PEG ratio of 33.57 during the Dec 2025 quarter over the past ten years. The Mar 2017 quarter had the bottom reading at 0.3, indicating the most optimal growth-adjusted valuation.
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| 2025 | 33.57 | 40.28 | 1.2% |
| 2024 | N/A | 48.53 | -15.4% |
| 2023 | 31.52 | 44.13 | 1.4% |
| 2022 | N/A | 29.9 | -11.5% |
| 2021 | 0.59 | 52.76 | 90% |
| 2020 | 1.4 | 60.54 | 43.1% |
| 2019 | 2.74 | 45.97 | 16.8% |
| 2018 | 0.94 | 35.01 | 37.3% |
| 2017 | 11.8 | 48.37 | 4.1% |
| 2016 | 0.91 | 43.28 | 47.4% |
| 2015 | N/A | 45.28 | -25.7% |
| 2014 | 2.66 | 29.74 | 11.2% |
| 2013 | 0.86 | 30.47 | 35.3% |
| 2012 | 3.65 | 23 | 6.3% |
| 2011 | 1.18 | 16.94 | 14.3% |
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| Mar 2026 | 1.95 | 33.33 | 17.1% |
| Dec 2025 | 33.57 | 40.28 | 1.2% |
| Sep 2025 | N/A | 38.63 | -0.3% |
| Jun 2025 | N/A | 32.56 | -5.5% |
| Mar 2025 | N/A | 34.87 | -16.3% |
| Dec 2024 | N/A | 48.53 | -15.4% |
| Sep 2024 | N/A | 44.08 | -9.3% |
| Jun 2024 | 21.06 | 46.33 | 2.2% |
| Mar 2024 | 14.74 | 51.59 | 3.5% |
| Dec 2023 | 31.52 | 44.13 | 1.4% |
| Sep 2023 | N/A | 49.96 | -10.9% |
| Jun 2023 | N/A | 54.95 | -24.2% |
| Mar 2023 | N/A | 46.76 | -19.3% |
| Dec 2022 | N/A | 29.9 | -11.5% |
| Sep 2022 | 15.36 | 29.19 | 1.9% |
When comparing to historical data, WST's PEG ratio comes in under the 3, 5 and 10-year averages.
With a PEG of 2.56, WST stands above the Healthcare sector and the industry average. In comparison with its Healthcare sector average of 0.55, West Pharmaceutical Services's PEG is 365% higher.
Among its peers, WST has a PEG ratio below stock MDT, while higher than SYK's and ICUI's.
| Stock name | PEG ratio | Market cap |
|---|---|---|
| ICUI Icu Medical Inc | 0.49 | $3.39B |
| SYK Stryker Corp | 2.15 | $118.84B |
| WST West Pharmaceutical Services Inc | 2.62 | $23.77B |
| MDT Medtronic plc | 6.52 | $103.21B |
| BDX Becton Dickinson & Co | N/A | $39.66B |
| BAX Baxter International Inc | N/A | $10.38B |
| TFX Teleflex Inc | N/A | $5.5B |
| JNJ Johnson & Johnson | N/A | $575.52B |
WST shows a PEG ratio of 2.56, per Jun 22, 2026 data.
WST shows a 3-year average PEG ratio of 20.57.
WST shows a 5-year average PEG ratio of 11.07.
The Dec 2025 quarter marked the ten years high at 33.57 for WST's PEG ratio.
Currently, WST's PEG ratio is 54% lower than its 10-year historical average.
The elevated PEG ratio of 2.56 indicates that WST may be overvalued relative to its earnings growth potential.
PEG equals PE divided by EPS growth rate (YoY TTM). As of Jun 22, 2026, West Pharmaceutical Services carries a P/E ratio of 43.84. Earnings grew at 17.1% over the TTM period ending Mar 2026. Applying the formula, this yields a price to earnings growth ratio of 2.56. PEG RATIO(2.56) = PE RATIO(43.84) / EPS GROWTH(17.1%)
All PEG ratio stats are based on quarterly TTM periods, unless otherwise specified.